

Please try another search
By Kim Khan
Investing.com - Gilead Sciences (NASDAQ:GILD) said after the bell Wednesday it will initiate two late-stage clinical trials for its drug remdesivir as a Covid-19 treatment.
About 1,000 patients will begin the trials in the beginning of March and “will assess two dosing durations of remdesivir, administered intravenously,” Gilead said in a press release.
The patients will come from “medical centers primarily across Asian countries, as well as other countries globally with high numbers of diagnosed cases.”
Shares of Gilead, up 6.56% in regular-session trading, added another 2.4% after the bell.
“The new clinical studies expand the ongoing research into remdesivir, which includes two clinical trials in China's Hubei province led by the China-Japan Friendship Hospital as well as the recently initiated clinical trial in the US led by the National Institute of Allergy and Infectious Diseases,” the company said.
Remdesivir is an antiviral that has been tested before in people infected with Ebola.
By Liz Hampton and Sabrina Valle (Reuters) - Top U.S. energy companies Chevron (NYSE:CVX) and Schlumberger (NYSE:SLB) have withdrawn an application to capture carbon dioxide...
By Raphael Satter WASHINGTON (Reuters) -The U.S. cybersecurity watchdog agency on Wednesday ordered federal officials to update or remove a slew of products made by digital...
Gabe Plotkin’s Melvin Capital Management, a hedge fund that lost billions after its bearish wagers were caught up in a Reddit-fueled rally of buying stocks including GameStop...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.